Document is current
Any future updates will be listed below
-
Authors
Lin, Joseph
Lin, Yueh-Te
Hsu, Kai-Wen
Liu, Yi-En
Chen, Yun-Cen
Yeh, Yung-Liang
Huang, Hsin-Ya
Hsieh, Chang-Chi
Chen, Dar-Ren
Wu, Han-Tsang
-
Funding
Funding for this research was provided by:
Chang Gung Memorial Hospital, Linkou (CMRPG3M1841)
Ministry of Science and Technology, Taiwan (MOST 111-2628-B-039-007-MY3, MOST-110-2314-B-371-007-MY3)
China Medical University, Taiwan (CMU112-MF-06)
Ministry of Education (the “Drug Development Center, China Medical University” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project)
Changhua Christian Hospital (112-CCH-IRP-090, 112-CCH-IRP-090)
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 12 February 2025
First Online: 21 February 2025
Declarations
:
: The animal experiment in this study followed the 3Rs guideline (Replacement, Reduction, Refinement) and was approved by the IACUC of Changhua Christian Hospital. The approval number is CCH-AE-107-010, and the approval date is 21 December 2018. The primary tumor was obtained from estrogen-receptor-positive breast cancer patients who underwent surgical resection at Changhua Christian Hospital. The approval number is 230724, and the approval date is 24 November 2023.
: The authors declare no competing interests.
